We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+10.52%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$413M
AUM Growth
-$28M
Cap. Flow
+$5.36M
Cap. Flow %
1.3%
Top 10 Hldgs %
93.04%
Holding
20
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACET icon
Adicet Bio
ACET
+$5.36M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$99.2M 24.03%
4,168,718
– –
VERA icon
2
Vera Therapeutics
VERA
$2.3B
$78.5M 19.03%
2,960,231
– –
JSPR icon
3
Jasper Therapeutics
JSPR
$21M
$44.1M 10.69%
562,856
– –
EFTR
4
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$39.9M 9.67%
192,885
– –
ACET icon
5
Adicet Bio
ACET
$85.2M
$36.9M 8.94%
132,212
+31,250
+31% +$5.36M
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$708M
$23.6M 5.72%
1,203,135
– –
SRRA
7
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$19.1M 4.62%
876,656
– –
OKUR
8
OnKure Therapeutics
OKUR
$154M
$17.7M 4.3%
207,396
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$16.3M 3.95%
2,457,499
– –
SIEN
10
DELISTED
Sientra, Inc.
SIEN
$8.6M 2.08%
234,983
– –
NCNA
11
NuCana
NCNA
$5.49M
$7.93M 1.92%
667
– –
PRTK
12
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.65M 1.13%
1,041,131
– –
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$4.22M 1.02%
686,840
– –
XCUR icon
14
Exicure
XCUR
$10.2M
$1.4M 0.34%
46,513
– –
SYRE icon
15
Spyre Therapeutics
SYRE
$8.54B
$1.14M 0.28%
9,620
– –
MTEM
16
DELISTED
Molecular Templates, Inc.
MTEM
$780K 0.19%
13,333
– –
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$442K 0.11%
131,036
– –
OBSV
18
DELISTED
ObsEva SA Ordinary Shares
OBSV
$174K 0.04%
87,999
– –
OCGN icon
19
Ocugen
OCGN
$416M
$32K 0.01%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2021 Portfolio in Review

As of Q4 2021, Abingworth held 20 positions worth $413M, down 6.3% from $441M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Trading was light in Q4 2021: portfolio turnover was 0%. Abingworth opened no new positions and made no exits, leaving the 20-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

  • Abingworth added most to Adicet Bio in Q4 2021, an estimated $5.36M increase.
  • Abingworth's ten largest holdings make up 93% of its $413M portfolio in Q4 2021.
  • Abingworth opened 0 new positions and closed 0 in Q4 2021.
  • Abingworth's portfolio value fell 6.3% quarter-over-quarter to $413M.

Based on Abingworth's 13F filing for Q4 2021, filed 16 Feb 2022.